clonazepam has been researched along with Idiopathic Parkinson Disease in 38 studies
Clonazepam: An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.
clonazepam : 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We used ramelteon to treat two patients with secondary REM sleep behavior disorder (RBD) complications along with neurodegenerative diseases including multiple system atrophy and Parkinson's disease." | 7.79 | Use of ramelteon for the treatment of secondary REM sleep behavior disorder. ( Kawase, S; Nakashima, K; Nomura, T; Watanabe, Y, 2013) |
| "Clonazepam is considered to be a first-line treatment for rapid eye movement sleep-related behavior disorder (RBD) in Parkinson's disease (PD)." | 6.90 | Clonazepam for probable REM sleep behavior disorder in Parkinson's disease: A randomized placebo-controlled trial. ( Jeon, B; Kim, HJ; Lee, WW; Park, H; Shin, C, 2019) |
| "The effect of long-acting propranolol hydrochloride (160 mg/d), primidone (250 mg at night), and clonazepam (4 mg/d) on the resting, postural, and kinetic component of tremor was investigated in ten parkinsonian patients in a double-blind crossover design." | 5.06 | Adjuvant therapy of parkinsonian tremor. ( Herbster, G; Koller, WC, 1987) |
| "A MEDLINE search (1977-April 2007) using the terms REM sleep behavior disorder, narcolepsy, parkinsonian disorders, levodopa, dopamine agonists, clonazepam, benzodiazepines, and melatonin was used to retrieve relevant articles." | 4.84 | Rapid eye movement sleep behavior disorder. ( Gugger, JJ; Wagner, ML, 2007) |
| "We used ramelteon to treat two patients with secondary REM sleep behavior disorder (RBD) complications along with neurodegenerative diseases including multiple system atrophy and Parkinson's disease." | 3.79 | Use of ramelteon for the treatment of secondary REM sleep behavior disorder. ( Kawase, S; Nakashima, K; Nomura, T; Watanabe, Y, 2013) |
| " The efficacy of clonazepam, a standard treatment choice for REM sleep behavior disorders, was investigated in 8 hallucinators." | 3.72 | Visual hallucinations as REM sleep behavior disorders in patients with Parkinson's disease. ( Inoue, Y; Kawahara, R; Mitani, H; Miyake, M; Nakashima, K; Nomura, T, 2003) |
| "Melatonin intake was associated with a higher decrease in RBDSQ score compared to trazodone (P = 0." | 3.11 | Safety and efficacy of melatonin, clonazepam, and trazodone in patients with Parkinson's disease and sleep disorders: a randomized, double-blind trial. ( Agah, E; Aghamollaii, V; Hadi, F; Mirsepassi, Z; Mousavi, SV; Tafakhori, A; Talachi, N; Tavanbakhsh, S, 2022) |
| "Thirty PD patients with rapid eye movement sleep behavior disorder were randomized to 4 mg of prolonged-release melatonin (Circadin) or matched placebo, ingested orally once-daily before bedtime." | 2.94 | Melatonin for rapid eye movement sleep behavior disorder in Parkinson's disease: A randomised controlled trial. ( Coeytaux Jackson, A; Fang, BAM; Gilat, M; Grunstein, RR; Hall, JM; Hammond, D; Lewis, SJG; Marshall, NS; Mullins, AE; Wong, KKH; Yee, BJ, 2020) |
| "Clonazepam is considered to be a first-line treatment for rapid eye movement sleep-related behavior disorder (RBD) in Parkinson's disease (PD)." | 2.90 | Clonazepam for probable REM sleep behavior disorder in Parkinson's disease: A randomized placebo-controlled trial. ( Jeon, B; Kim, HJ; Lee, WW; Park, H; Shin, C, 2019) |
| "We studied 38 patients with Parkinson's disease (PD) without dementia (mean age, 67." | 2.77 | [Sleep disorders in Parkinson's disease without dementia: a comparative randomized controlled study of melatonin and clonazepam]. ( Krasakov, IV; Litvinenko, IV; Tikhomirova, OV, 2012) |
| "Clonazepam has a definite role in the management of parkinsonian dysarthria." | 2.66 | A double-blind trial of clonazepam in the treatment of parkinsonian dysarthria. ( Biary, N; Langenberg, PW; Pimental, PA, 1988) |
| "Patients with rapid eye movement sleep behavior disorder are frequently prone to sleep-related injuries and should be treated to prevent injury with either melatonin 3-12 mg or clonazepam 0." | 2.55 | REM Sleep Behavior Disorder in Parkinson's Disease and Other Synucleinopathies. ( Boeve, AR; Boeve, BF; St Louis, EK, 2017) |
| "Patients with Parkinson's disease should be examined by polysomnography as the clinical interview's sensitivity alone can hardly reach 33%." | 2.43 | REM sleep behavior disorder in patients with Parkinson's disease. ( Poryazova, RG; Zachariev, ZI, 2005) |
| "Tremor-predominant Parkinson's disease is characterised by prominent tremor of one or more limbs with a relative lack of significant rigidity and bradykinesia." | 2.41 | Tremor-predominant Parkinson's disease. Approaches to treatment. ( Koller, W; Marjama-Lyons, J, 2000) |
| "Psychotic features in patients with Parkinson's Disease usually present as visual hallucinations against a background of cognitive deterioration and dopaminomimetic therapy." | 1.36 | Isolated delusional syndrome in Parkinson's Disease. ( Bozi, M; Christodoulou, C; Douzenis, A; Gasparinatos, G; Stamboulis, E; Stefanis, C; Stefanis, L; Stefanis, N, 2010) |
| "Based on chart review, patients with Parkinson's disease whose bed partners have reported prominent motor activity while dreaming were identified." | 1.33 | Clinical features of 35 patients with Parkinson's disease displaying REM behavior disorder. ( Apaydin, H; Kiliç, E; Ozekmekçi, S, 2005) |
| "To investigate excessive daytime sleepiness (EDS) in patients with Parkinson's disease (PD), the reasons for which have not yet been clarified, polysomnography (PSG) and the Multiple Sleep Latency Test (MSLT) were performed in 46 patients with PD, and, in addition, PSG was performed in 30 healthy controls." | 1.33 | Excessive daytime sleepiness in patients with Parkinson's disease: a polysomnography study. ( Goldstein, R; Klein, C; Miniovitz, A; Pollak, L; Prokhorov, T; Rabey, JM; Shpirer, I; Theitler, J, 2006) |
| "Clonazepam treatment of RBD was completely or partially successful in 87% of the patients who used the drug." | 1.31 | Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. ( Boeve, BF; Olson, EJ; Silber, MH, 2000) |
| "We describe three cases of fast orthostatic tremor (FoT) of legs and trunk mimicking primary orthostatic tremor (OT) in patients treated with levodopa for PD." | 1.31 | Fast orthostatic tremor in Parkinson's disease mimicking primary orthostatic tremor. ( Apartis, E; Arné, P; Jedynak, CP; Tison, F; Vidailhet, M, 2001) |
| "However, a number of presumed Parkinson's disease patients may eventually be diagnosed with multiple system atrophy (striatonigral degeneration subtype)." | 1.29 | Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. ( Bundlie, SR; Mahowald, MW; Schenck, CH, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (15.79) | 18.7374 |
| 1990's | 3 (7.89) | 18.2507 |
| 2000's | 13 (34.21) | 29.6817 |
| 2010's | 11 (28.95) | 24.3611 |
| 2020's | 5 (13.16) | 2.80 |
| Authors | Studies |
|---|---|
| Ko, YF | 1 |
| Kuo, PH | 1 |
| Wang, CF | 1 |
| Chen, YJ | 1 |
| Chuang, PC | 1 |
| Li, SZ | 1 |
| Chen, BW | 1 |
| Yang, FC | 1 |
| Lo, YC | 1 |
| Yang, Y | 1 |
| Ro, SV | 1 |
| Jaw, FS | 1 |
| Lin, SH | 1 |
| Chen, YY | 1 |
| Hadi, F | 1 |
| Agah, E | 1 |
| Tavanbakhsh, S | 1 |
| Mirsepassi, Z | 1 |
| Mousavi, SV | 1 |
| Talachi, N | 1 |
| Tafakhori, A | 1 |
| Aghamollaii, V | 1 |
| Dodet, P | 1 |
| Gilat, M | 1 |
| Coeytaux Jackson, A | 1 |
| Marshall, NS | 1 |
| Hammond, D | 1 |
| Mullins, AE | 1 |
| Hall, JM | 1 |
| Fang, BAM | 1 |
| Yee, BJ | 1 |
| Wong, KKH | 1 |
| Grunstein, RR | 1 |
| Lewis, SJG | 1 |
| Iranzo, A | 4 |
| Ramos, LA | 1 |
| Novo, S | 1 |
| Hsu, CH | 1 |
| Yu, SM | 1 |
| Lau, SC | 1 |
| Chen, YL | 1 |
| Pei, D | 1 |
| Liu, IC | 1 |
| St Louis, EK | 1 |
| Boeve, AR | 1 |
| Boeve, BF | 3 |
| Dauvilliers, Y | 2 |
| Schenck, CH | 4 |
| Postuma, RB | 1 |
| Luppi, PH | 2 |
| Plazzi, G | 2 |
| Montplaisir, J | 1 |
| Boeve, B | 1 |
| Shin, C | 1 |
| Park, H | 1 |
| Lee, WW | 1 |
| Kim, HJ | 2 |
| Jeon, B | 1 |
| Montplaisir, JY | 1 |
| Frauscher, B | 1 |
| Hogl, B | 1 |
| Gagnon, JF | 1 |
| Postuma, R | 1 |
| Sonka, K | 1 |
| Jennum, P | 1 |
| Partinen, M | 2 |
| Arnulf, I | 1 |
| Cochen de Cock, V | 1 |
| Heidbreder, A | 1 |
| Mayer, G | 1 |
| Sixel-Döring, F | 1 |
| Trenkwalder, C | 1 |
| Unger, M | 1 |
| Young, P | 1 |
| Wing, YK | 1 |
| Ferini-Strambi, L | 1 |
| Ferri, R | 1 |
| Zucconi, M | 1 |
| Inoue, Y | 3 |
| Santamaria, J | 2 |
| Bassetti, C | 1 |
| Möller, JC | 1 |
| Lai, YY | 1 |
| Pavlova, M | 1 |
| Saper, C | 1 |
| Schmidt, P | 1 |
| Siegel, JM | 1 |
| Singer, C | 1 |
| St Louis, E | 1 |
| Videnovic, A | 1 |
| Oertel, W | 1 |
| Nomura, T | 3 |
| Kawase, S | 1 |
| Watanabe, Y | 1 |
| Nakashima, K | 3 |
| Canepa, C | 1 |
| Bodkin, CL | 1 |
| Lauterbach, EC | 1 |
| Victoroff, J | 1 |
| Coburn, KL | 1 |
| Shillcutt, SD | 1 |
| Doonan, SM | 1 |
| Mendez, MF | 1 |
| Stefanis, N | 1 |
| Bozi, M | 1 |
| Christodoulou, C | 1 |
| Douzenis, A | 1 |
| Gasparinatos, G | 1 |
| Stamboulis, E | 1 |
| Stefanis, C | 1 |
| Stefanis, L | 1 |
| Ylikoski, A | 1 |
| Litvinenko, IV | 1 |
| Krasakov, IV | 1 |
| Tikhomirova, OV | 1 |
| Mitani, H | 1 |
| Kawahara, R | 1 |
| Miyake, M | 1 |
| Cersosimo, MG | 1 |
| Koller, WC | 2 |
| Visch, HJ | 1 |
| Rutter, GA | 1 |
| Koopman, WJ | 1 |
| Koenderink, JB | 1 |
| Verkaart, S | 1 |
| de Groot, T | 1 |
| Varadi, A | 1 |
| Mitchell, KJ | 1 |
| van den Heuvel, LP | 1 |
| Smeitink, JA | 1 |
| Willems, PH | 1 |
| Ozekmekçi, S | 1 |
| Apaydin, H | 1 |
| Kiliç, E | 1 |
| Rye, DB | 1 |
| Valldeoriola, F | 1 |
| Martí, MJ | 1 |
| Muñoz, E | 1 |
| Vilaseca, I | 1 |
| Tolosa, E | 1 |
| Poryazova, RG | 1 |
| Zachariev, ZI | 1 |
| Shpirer, I | 1 |
| Miniovitz, A | 1 |
| Klein, C | 1 |
| Goldstein, R | 1 |
| Prokhorov, T | 1 |
| Theitler, J | 1 |
| Pollak, L | 1 |
| Rabey, JM | 1 |
| Gugger, JJ | 1 |
| Wagner, ML | 1 |
| Noda, K | 1 |
| Isozaki, E | 1 |
| Miyamoto, K | 1 |
| Hirose, K | 1 |
| Tanabe, H | 1 |
| Oda, M | 1 |
| Bundlie, SR | 1 |
| Mahowald, MW | 1 |
| Olson, EJ | 1 |
| Silber, MH | 1 |
| Marjama-Lyons, J | 1 |
| Koller, W | 1 |
| Apartis, E | 1 |
| Tison, F | 1 |
| Arné, P | 1 |
| Jedynak, CP | 1 |
| Vidailhet, M | 1 |
| Loeb, C | 1 |
| Priano, A | 1 |
| Lloyd, GK | 1 |
| Lowenthal, A | 1 |
| Javoy-Agid, F | 1 |
| Constantidinis, J | 1 |
| Biary, N | 1 |
| Pimental, PA | 1 |
| Langenberg, PW | 1 |
| Giménez-Roldán, S | 1 |
| Mateo, D | 1 |
| Orbe, M | 1 |
| Muñoz-Blanco, JL | 1 |
| Hípola, D | 1 |
| Lang, AE | 1 |
| Obeso, JA | 1 |
| Rothwell, JC | 1 |
| Marsden, CD | 1 |
| Herbster, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Double-Blind, Double-Dummy, Crossover Study to Evaluate the Efficacy and Safety of Prolonged-Release Melatonin and Clonazepam in Patients With Rapid Eye Movement (REM) Sleep Behavior Disorder in Parkinson Disease[NCT02789592] | Phase 2 | 30 participants (Anticipated) | Interventional | 2016-07-31 | Not yet recruiting | ||
| DREAMER - IsolateD REM Sleep Without Atonia as a Risk Factor for REM Sleep Behavior disordER: Constitution of a Cohort for a Long-term Prospective Follow-up Study[NCT06140511] | 600 participants (Anticipated) | Observational | 2023-11-20 | Not yet recruiting | |||
| A Single Center, Open Label Prospective Observational Pilot Study to Evaluate the Effects of Tasimelteon in Participants With REM Behavior Disorder (RBD)[NCT05922995] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2023-09-30 | Not yet recruiting | ||
| The Effect of alpha1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study[NCT05109364] | Phase 2 | 15 participants (Anticipated) | Interventional | 2022-09-23 | Recruiting | ||
| Efficacy and Tolerability of Ramelteon in Patients With REM Behavior Disorder and Parkinsonism: A Placebo Controlled, Double Blind, Randomized, Prospective Pilot Study[NCT00745030] | 3 participants (Actual) | Interventional | 2008-06-30 | Terminated (stopped due to Low subject recruitment and enrollment.) | |||
| Effect of Clonazepam on REM Sleep Behavior Disorder in Patients With Parkinsonism: a Prospective, Randomized, Double-blind and Placebo-controlled Trial[NCT02312908] | Phase 2 | 40 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for clonazepam and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
REM behavior disorder: When Parkinson's disease meets Morpheus.
Topics: Aged; Clonazepam; Humans; Melatonin; Parkinson Disease; REM Sleep Behavior Disorder; Synucleinopathi | 2023 |
The Isolated Form of Rapid Eye Movement Sleep Behavior Disorder: The Upcoming Challenges.
Topics: Clonazepam; Dementia; Diagnostic Tests, Routine; Humans; Melatonin; Parkinson Disease; REM Sleep Beh | 2021 |
REM Sleep Behavior Disorder in Parkinson's Disease and Other Synucleinopathies.
Topics: Central Nervous System Depressants; Clonazepam; GABA Modulators; Humans; Lewy Body Disease; Melatoni | 2017 |
REM sleep behaviour disorder.
Topics: alpha-Synuclein; Antidepressive Agents; Central Nervous System Depressants; Clonazepam; Diagnosis, D | 2018 |
Rapid eye movement sleep behavior disorder in women: relevance to general and specialty medical practice.
Topics: Clonazepam; Diagnosis, Differential; Disease Progression; Early Diagnosis; Female; GABA Modulators; | 2009 |
Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipsychotic Agents; Benzodiazepines; Benzo | 2010 |
[REM sleep behavior disorder (RBD)].
Topics: Clonazepam; Diagnosis, Differential; GABA Modulators; Humans; Melatonin; Parkinson Disease; Polysomn | 2012 |
REM sleep behavior disorder in patients with Parkinson's disease.
Topics: Anticonvulsants; Antiparkinson Agents; Clonazepam; Humans; Levodopa; Parkinson Disease; Polysomnogra | 2005 |
Rapid eye movement sleep behavior disorder.
Topics: Anticonvulsants; Antiparkinson Agents; Benzothiazoles; Clonazepam; Comorbidity; Dopamine Agonists; G | 2007 |
Tremor-predominant Parkinson's disease. Approaches to treatment.
Topics: Acetates; Amantadine; Amines; Antiparkinson Agents; Botulinum Toxins; Cholinergic Antagonists; Clona | 2000 |
Somatosensory evoked potentials in myoclonus.
Topics: Brain Diseases, Metabolic; Cerebral Cortex; Clonazepam; Electroencephalography; Electromyography; Ev | 1986 |
7 trials available for clonazepam and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Quantification Analysis of Sleep Based on Smartwatch Sensors for Parkinson's Disease.
Topics: Algorithms; Clonazepam; Humans; Parkinson Disease; REM Sleep Behavior Disorder; Sleep | 2022 |
Safety and efficacy of melatonin, clonazepam, and trazodone in patients with Parkinson's disease and sleep disorders: a randomized, double-blind trial.
Topics: Clonazepam; Double-Blind Method; Humans; Iran; Melatonin; Parkinson Disease; Sleep Wake Disorders; T | 2022 |
Melatonin for rapid eye movement sleep behavior disorder in Parkinson's disease: A randomised controlled trial.
Topics: Aged; Clonazepam; Double-Blind Method; Eye Movements; Fatigue; Female; Humans; Male; Melatonin; Midd | 2020 |
Clonazepam for probable REM sleep behavior disorder in Parkinson's disease: A randomized placebo-controlled trial.
Topics: Aged; Anticonvulsants; Clonazepam; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Mid | 2019 |
[Sleep disorders in Parkinson's disease without dementia: a comparative randomized controlled study of melatonin and clonazepam].
Topics: Aged; Antioxidants; Clonazepam; Drug Therapy, Combination; Female; Humans; Male; Melatonin; Middle A | 2012 |
A double-blind trial of clonazepam in the treatment of parkinsonian dysarthria.
Topics: Aged; Clinical Trials as Topic; Clonazepam; Double-Blind Method; Dysarthria; Humans; Middle Aged; Pa | 1988 |
Adjuvant therapy of parkinsonian tremor.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clonazepam; Double-Blind Method; Drug Therapy, Combination; H | 1987 |
20 other studies available for clonazepam and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Restless legs syndrome/Willis-Ekbom disease in type 2 diabetes as the initial manifestation of Parkinson's disease and major cardiovascular disease.
Topics: Aged; Amines; Analgesics; Anticonvulsants; Antihypertensive Agents; Antiparkinson Agents; Aspirin; B | 2017 |
Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy--a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group.
Topics: Clinical Trials as Topic; Clonazepam; Consensus; GABA Modulators; Humans; Melatonin; Neuroprotective | 2013 |
Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy--a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group.
Topics: Clinical Trials as Topic; Clonazepam; Consensus; GABA Modulators; Humans; Melatonin; Neuroprotective | 2013 |
Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy--a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group.
Topics: Clinical Trials as Topic; Clonazepam; Consensus; GABA Modulators; Humans; Melatonin; Neuroprotective | 2013 |
Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy--a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group.
Topics: Clinical Trials as Topic; Clonazepam; Consensus; GABA Modulators; Humans; Melatonin; Neuroprotective | 2013 |
Use of ramelteon for the treatment of secondary REM sleep behavior disorder.
Topics: Aged; Clonazepam; Female; Humans; Indenes; Male; Middle Aged; Multiple System Atrophy; Parkinson Dis | 2013 |
Park sleep: a non-motor dominant Parkinson's disease phenotype.
Topics: Aged; Clonazepam; Humans; Levodopa; Male; Parkinson Disease; REM Sleep Behavior Disorder | 2016 |
Isolated delusional syndrome in Parkinson's Disease.
Topics: Aged; Amantadine; Antiparkinson Agents; Benserazide; Benzothiazoles; Catechols; Clonazepam; Female; | 2010 |
Visual hallucinations as REM sleep behavior disorders in patients with Parkinson's disease.
Topics: Aged; Anticonvulsants; Antiparkinson Agents; Cerebral Cortex; Circadian Rhythm; Clinical Trials as T | 2003 |
Movement disorders.
Topics: Adult; Aged; Anticonvulsants; Atrophy; Brain; Child; Clonazepam; Diagnosis, Differential; Female; Hu | 2003 |
Inhibition of mitochondrial Na+-Ca2+ exchange restores agonist-induced ATP production and Ca2+ handling in human complex I deficiency.
Topics: Adenosine Triphosphate; Bradykinin; Calcium; Cell Nucleus; Clonazepam; Cytosol; Electron Transport C | 2004 |
Clinical features of 35 patients with Parkinson's disease displaying REM behavior disorder.
Topics: Age Factors; Aged; Antiparkinson Agents; Case-Control Studies; Clonazepam; Dyskinesias; Female; GABA | 2005 |
Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD.
Topics: Age of Onset; Aged; Anticonvulsants; Brain; Clonazepam; Female; Humans; Logistic Models; Male; Middl | 2005 |
Excessive daytime sleepiness in patients with Parkinson's disease: a polysomnography study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benzodiazepines; Clonazepam; Cohort Studies; Comorbid | 2006 |
Clinical characteristics of Restless legs syndrome in patients with Parkinson's disease.
Topics: Age of Onset; Aged; Aging; Anticonvulsants; Clonazepam; Dopamine; Dopamine Agonists; Dose-Response R | 2006 |
[Rhythmical involuntary movement at rest associated with olivo-ponto-cerebellar atrophy (OPCA)].
Topics: Adolescent; Aged; Brain; Clonazepam; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; | 1993 |
Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder.
Topics: Brain; Clonazepam; Electromyography; Follow-Up Studies; GABA Modulators; Humans; Magnetic Resonance | 1996 |
Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder.
Topics: Brain; Clonazepam; Electromyography; Follow-Up Studies; GABA Modulators; Humans; Magnetic Resonance | 1996 |
Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder.
Topics: Brain; Clonazepam; Electromyography; Follow-Up Studies; GABA Modulators; Humans; Magnetic Resonance | 1996 |
Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder.
Topics: Brain; Clonazepam; Electromyography; Follow-Up Studies; GABA Modulators; Humans; Magnetic Resonance | 1996 |
Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Aging; Anticonvulsants; Atrophy; Brain; Clonazepam; De | 2000 |
Fast orthostatic tremor in Parkinson's disease mimicking primary orthostatic tremor.
Topics: Aged; Anti-Anxiety Agents; Antiparkinson Agents; Clonazepam; Electromyography; Female; Humans; Leg; | 2001 |
Preliminary evaluation of the effects of clonazepam on parkinsonian tremor.
Topics: Benzodiazepinones; Clonazepam; Drug Evaluation; Humans; Parkinson Disease; Tremor | 1977 |
GABAA receptor complex function in frontal cortex membranes from control and neurological patients.
Topics: Adult; Aged; Alzheimer Disease; Bridged Bicyclo Compounds; Bridged Bicyclo Compounds, Heterocyclic; | 1991 |
Acute pharmacologic tests in cranial dystonia.
Topics: Adult; Aged; Basal Ganglia Diseases; Clonazepam; Diagnosis, Differential; Double-Blind Method; Femal | 1988 |
Restless legs syndrome and Parkinson's disease: insights into pathophysiology.
Topics: Aged; Clonazepam; Codeine; Dopamine; Humans; Levodopa; Male; Parkinson Disease; Restless Legs Syndro | 1987 |